Tissue chips – innovative tools for drug development and disease modeling

Low, Lucie A.; Tagle, Danilo A.

doi:10.1039/c7lc00462a

“…The obstacles cut across a broad spectrum that range from cell sourcing and maturity issues to platform design using appropriate materials and fit-for-purpose cell scaffolds. 36,37 As a starting point, the NIH has guidelines for cell authenticity (see ''https://grants.nih.gov/grants/guide/ notice-files/NOT-OD-17-068.html'' Authentication of Key Biological and/or Chemical Resources'') and for NIH-funded human stem cell research (https://stemcells.nih.gov/ policy/2009-guidelines.htm). The National Center for Advancing Translational Sciences (NCATS) at the U.S. NIH has supported a number of efforts to catalyze the tissue-on-a-chip field and to spur the validation and commercialization efforts of the technology.…”

Section: Enable Scalabilitymentioning

confidence: 99%

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development

Wright

¹

,

Becker

²

,

Low

³

et al. 2020

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

In this study, we describe efforts by the National Eye Institute (NEI) and National Center for Advancing Translational Science (NCATS) to catalyze advances in 3-dimensional (3-D) ocular organoid and microphysiological systems ( MPS). We reviewed the recent literature regarding ocular organoids and tissue chips. Animal models, 2-dimensional cell culture models, and postmortem human tissue samples provide the vision research community with insights critical to understanding pathophysiology and therapeutic development. The advent of induced pluripotent stem cell technologies provide researchers with enticing new approaches and tools that augment study in more traditional models to provide the scientific community with insights that have previously been impossible to obtain. Efforts by the National Institutes of Health (NIH) have already accelerated the pace of scientific discovery, and recent advances in ocular organoid and MPS modeling approaches have opened new avenues of investigation. In addition to more closely recapitulating the morphologies and physiological responses of in vivo human tissue, key breakthroughs have been made in the past year to resolve long-standing scientific questions regarding tissue development, molecular signaling, and pathophysiological mechanisms that promise to provide advances critical to therapeutic development and patient care. 3-D tissue culture modeling and MPS offer platforms for future high-throughput testing of therapeutic candidates and studies of gene interactions to improve models of complex genetic diseases with no well-defined etiology, such as age-related macular degeneration and Fuchs' dystrophy.

show abstract

“…The FDA will require clear and unequivocal evidence for the cellular basis of stem/progenitor–based therapies for musculoskeletal tissue repair. A combination of models will provide support for cell‐based therapeutics, including in vitro three‐dimensional models of tissue regeneration/tissue chip models, small‐animal models; and large‐animal models. Fundamental requirements for adequate interpretation of cell‐based therapies include the ability to: (i) track the donor cell population; (ii) determine cellular fate and differentiation; and (iii) define the role of the cell population in restoring a stable and mechanically functional tissue.…”

Section: Key Question 5: What Are the Task Force Recommendations For mentioning

confidence: 99%

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

O’Keefe

¹

,

Tuan

²

,

Lane

³

et al. 2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:485–502, 2020

show abstract

“…A combination of models will provide support for cellbased therapeutics, including in vitro three-dimensional models of tissue regeneration/tissue chip models, (110) small-animal models; and large-animal models. A combination of models will provide support for cellbased therapeutics, including in vitro three-dimensional models of tissue regeneration/tissue chip models, (110) small-animal models; and large-animal models.…”

Section: Preclinical Animal Modelsmentioning

confidence: 99%

“…The FDA will require clear and unequivocal evidence for the cellular basis of stem/progenitor-based therapies for musculoskeletal tissue repair. A combination of models will provide support for cellbased therapeutics, including in vitro three-dimensional models of tissue regeneration/tissue chip models, (110) small-animal models; and large-animal models. Fundamental requirements for adequate interpretation of cell-based therapies include the ability to: (i) track the donor cell population; (ii) determine cellular fate and differentiation; and (iii) define the role of the cell population in restoring a stable and mechanically functional tissue.…”

Section: Preclinical Animal Modelsmentioning

confidence: 99%

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

O’Keefe

¹

,

Tuan

²

,

Lane

³

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2019 American Society for Bone and Mineral Research.

show abstract

Tissue chips – innovative tools for drug development and disease modeling

Cited by 110 publications

References 101 publications

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies

Contact Info

Product

Resources

About